% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{AfsharOromieh:141171,
      author       = {A. Afshar-Oromieh and N. Debus and M. Uhrig$^*$ and T. A.
                      Hope and M. J. Evans and T. Holland-Letz$^*$ and F. L.
                      Giesel and K. Kopka$^*$ and B. Hadaschik and C. Kratochwil
                      and U. Haberkorn$^*$},
      title        = {{I}mpact of long-term androgen deprivation therapy on
                      {PSMA} ligand {PET}/{CT} in patients with
                      castration-sensitive prostate cancer.060},
      journal      = {European journal of nuclear medicine and molecular imaging},
      volume       = {45},
      number       = {12},
      issn         = {1619-7089},
      address      = {Heidelberg [u.a.]},
      publisher    = {Springer-Verl.},
      reportid     = {DKFZ-2018-01698},
      pages        = {2045 - 2054},
      year         = {2018},
      abstract     = {Since the introduction of PSMA PET/CT with 68Ga-PSMA-11,
                      this modality for imaging prostate cancer (PC) has spread
                      worldwide. Preclinical studies have demonstrated that
                      short-term androgen deprivation therapy (ADT) can
                      significantly increase PSMA expression on PC cells.
                      Additionally, retrospective clinical data in large patient
                      cohorts suggest a positive association between ongoing ADT
                      and a pathological PSMA PET/CT scan. The present evaluation
                      was conducted to further analyse the influence of long-term
                      ADT on PSMA PET/CT findings.A retrospective analysis was
                      performed of all 1,704 patients who underwent a 68Ga-PSMA-11
                      PET/CT scan at our institution from 2011 to 2017 to detect
                      PC. Of 306 patients scanned at least twice, 10 had started
                      and continued ADT with a continuous clinical response
                      between the two PSMA PET/CT scans. These ten patients were
                      included in the current analysis which compared the tracer
                      uptake intensity and volume of PC lesions on PSMA PET/CT
                      before and during ongoing ADT.Overall, 31 PC lesions were
                      visible in all ten patients before initiation of ADT.
                      However, during ongoing ADT (duration 42-369 days, median
                      230 days), only 14 lesions were visible in eight of the ten
                      patients. The average tracer uptake values decreased in
                      $71\%$ and increased in $12.9\%$ of the PC lesions. Of all
                      lesions, $33.3\%$ were still visible in six patients with a
                      complete PSA response (≤0.1 ng/ml).Continuous long-term
                      ADT significantly reduces the visibility of
                      castration-sensitive PC on PSMA PET/CT. If the objective is
                      visualization of the maximum possible extent of disease, we
                      recommend referring patients for PSMA PET/CT before starting
                      ADT.},
      cin          = {E010 / C060 / E030 / E060},
      ddc          = {610},
      cid          = {I:(DE-He78)E010-20160331 / I:(DE-He78)C060-20160331 /
                      I:(DE-He78)E030-20160331 / I:(DE-He78)E060-20160331},
      pnm          = {315 - Imaging and radiooncology (POF3-315)},
      pid          = {G:(DE-HGF)POF3-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:29980832},
      pmc          = {pmc:PMC6182397},
      doi          = {10.1007/s00259-018-4079-z},
      url          = {https://inrepo02.dkfz.de/record/141171},
}